GLP-1 receptor agonist research, from glycaemic control to body-weight outcomes.
20 articles
Weight Loss & GLP-1
The top 10 most-researched peptides of 2025 ranked by published study volume, mechanistic depth, and research versatility. Covering BPC-157, TB-500, semaglutide, ipamorelin, SS-31, retatrutide, PT-141, CJC-1295, tirzepatide, and NAD+ precursor peptides with their current research status.
6 min read
Peptides & Recovery
Semaglutide-based metabolic research protocols use diet-induced obesity (DIO) rodent models to study GLP-1R-mediated weight loss, glycemic improvement, and lipid remodeling. Guide to the semaglutide DIO research stack — compound selection, protocol design, dose escalation, and endpoints.
4 min read
Peptides & Recovery
Semaglutide is a complex acylated GLP-1 analog requiring HPLC-MS identity verification and high purity COA for legitimate research use. Guide for European researchers on semaglutide quality requirements, EU supply advantages, and what distinguishes research-grade semaglutide from substandard supply.
3 min read
Weight Loss & GLP-1
A comprehensive guide to sourcing research peptides in Europe — what quality standards to require, how EU supply chains differ from US suppliers, EU regulatory context, and why independent COA testing is the non-negotiable baseline for legitimate European research peptide supply.
4 min read
Peptides & Recovery
GLP-1 receptor agonists improve insulin resistance through multiple mechanisms beyond GLP-1R signaling — including hepatic gluconeogenesis suppression, adipose tissue remodeling, and GIP receptor co-stimulation. Advanced research guide to GLP-1 insulin sensitization pathways and experimental models.
5 min read
Weight Loss & GLP-1
Semaglutide, retatrutide, and tirzepatide represent three generations of incretin-based therapy with distinct receptor targets. Research comparison of mechanisms, clinical trial weight loss data, receptor pharmacology, and research applications for each compound class.
4 min read
Weight Loss & GLP-1
GLP-1 receptor agonists are among the most studied compounds in metabolic biology research. Protocol design guide covering GLP-1/GIP/GCG receptor mechanisms, compound selection for obesity and glucose homeostasis research, and in vitro and in vivo endpoint design.
4 min read
Weight Loss & GLP-1
Understanding fair market pricing for research peptides, SARMs, anabolic steroids, and GLP-1 agonists in the European market. What drives price differences, what pricing signals quality vs. cost-cutting, and how to evaluate value for research budgets.
4 min read
Weight Loss & GLP-1
Semaglutide for laboratory research in Europe requires high purity HPLC-MS verified compound, proper cold-chain logistics, and verifiable third-party testing. Research procurement guide for semaglutide in the European market.
4 min read
Weight Loss & GLP-1
Improper storage of research compounds — peptides, steroids, SARMs, and GLP-1 agonists — causes degradation that invalidates experimental results. Complete storage guide covering temperature requirements, light sensitivity, humidity, and practical lab storage solutions.
4 min read
Weight Loss & GLP-1
A mechanistically rational weight loss research stack combining semaglutide, retatrutide, HGH Fragment 176-191, and MOTS-c — covering appetite suppression, thermogenesis, lipolysis, and metabolic enhancement in one protocol.
7 min read
Peptides & Recovery
Head-to-head research comparison of retatrutide (triple agonist) vs semaglutide (GLP-1 agonist) — mechanism differences, weight loss magnitude, glycemic control, side effect profiles, and research protocol selection.
7 min read
Weight Loss & GLP-1
How semaglutide controls blood glucose through GLP-1R-mediated insulin secretion, glucagon suppression, and gastric emptying slowing — with clinical trial HbA1c data and mechanistic analysis.
8 min read
Weight Loss & GLP-1
A comprehensive overview of the GLP-1 receptor agonist drug class — mechanism, clinical evolution from exenatide to semaglutide, and the expanding role of GLP-1R signaling in metabolic disease, cardiovascular health, and neuroscience.
8 min read
Weight Loss & GLP-1
A research-focused analysis of semaglutide's adverse effect profile — nausea, thyroid C-cell findings, pancreatitis signal, and rare events — with mechanistic explanations from GLP-1R pharmacology.
8 min read
Weight Loss & GLP-1
Semaglutide requires gradual dose escalation to minimize GI side effects. This guide covers escalation schedules used in clinical trials and their rodent-equivalent adaptations for research protocols.
6 min read
Weight Loss & GLP-1
Comparing semaglutide administration via pharmaceutical auto-injector pen vs. research-grade vial reconstitution — accuracy, flexibility, storage, and which is appropriate for laboratory research protocols.
6 min read
Peptides & Recovery
Ozempic, Wegovy, and Rybelsus are all semaglutide. This research guide explains the difference — dose, indication, formulation — and what researchers need to know when selecting the appropriate form.
6 min read
Peptides & Recovery
Semaglutide produces 15–17% body weight loss via CNS appetite suppression, slowed gastric emptying, and altered food reward signaling. This deep-dive covers every mechanism behind GLP-1 induced weight loss.
8 min read
Peptides & Recovery
Semaglutide is a GLP-1 receptor agonist developed by Novo Nordisk and widely researched for weight loss and glycemic control. This overview covers its structure, mechanism, pharmacokinetics, and research applications.
8 min read
Hilma Biocare
GLP-1 receptor agonist. The active compound in Ozempic/Wegovy research.
99.0%· Janoshik
Hilma Biocare
Pre-filled semaglutide pen. Convenient auto-injector for research use.
99.0%· Janoshik
ZPHC
Semaglutide 5mg kit (5×1mg) by ZPHC. GLP-1 receptor agonist.
99%+· ZPHC
ZPHC
Semaglutide 10mg kit (5×2mg) by ZPHC. Best-value GLP-1 research kit.
99%+· ZPHC
For laboratory research only. Not for human consumption.
Resellers, laboratories and publishers: apply for partner pricing, volume terms and a dedicated representative.
Research use only. All products are sold strictly for in-vitro and laboratory research. Not for human consumption, veterinary use, diagnosis, treatment or prevention of any disease. Products sold by JuicedPharma are not medicines. By ordering you confirm you are a qualified person buying for research in compliance with applicable regulations. Full disclaimer